Curanex Pharmaceuticals Common Stock

CURX | NASDAQ

$5.29

+$0.35 (+7.09%)

At close: Oct 30, 2026, 3:59 PM ET

$5.10

-$0.19 (-3.63%)

Pre-market: Nov 2, 2026, 4:00 AM ET

Fiscal Quarter Period Ending	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q2 2024 Jun 30, 2024
Net Income	-3.29M	-3.15M	-3.07M	-954.06K	-60.35K	-137.58K	-44.2K
Depreciation & Amortization	36.64K	35.04K	34.29K	15.44K	15.03K	14.63K	n/a
Stock-Based Compensation	n/a	9.79K	n/a	n/a	n/a	n/a	n/a
Other Working Capital	2.19M	2.14M	2.29M	-8.48M	-118.98K	-148.06K	-192.13K
Other Non-Cash Items	-5.98K	5.98K	n/a	113.94K	n/a	n/a	n/a
Deferred Income Tax	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Change in Working Capital	2.18M	2.14M	2.18M	-8.36M	-244.77K	-27K	-192.13K
Operating Cash Flow	-1.08M	-954.56K	-857.4K	-9.19M	-290.08K	-149.95K	-236.33K
Capital Expenditures	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cash Acquisitions	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Purchase of Investments	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Sales Maturities Of Investments	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Investing Acitivies	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Investing Cash Flow	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Debt Repayment	n/a	n/a	n/a	-400K	200K	200K	n/a
Common Stock Repurchased	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	n/a	n/a	n/a	-346.5K	n/a	n/a	100
Financial Cash Flow	n/a	n/a	n/a	14.91M	200K	200K	580.1K
Net Cash Flow	-1.08M	-954.56K	-857.4K	5.72M	-90.08K	50.05K	343.77K
Free Cash Flow	-1.08M	-954.56K	-857.4K	-9.19M	-290.08K	-149.95K	-236.33K
Adj. Free Cash Flow	-1.08M	-964.35K	-857.4K	-9.19M	-290.08K	-149.95K	-236.33K
Maintenance CapEx	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Growth CapEx	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Owner Earnings	-1.08M	-954.56K	-857.4K	-9.19M	-290.08K	-149.95K	-236.33K